Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies (Q46757961)

http://europepmc.org/abstract/PMC/5767160

22 February 2018

title

Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies (English)

1 reference

http://europepmc.org/abstract/PMC/5767160

22 February 2018

1 reference

1 reference

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27533448%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Adil Daud

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27533448%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Jeffrey S Weber

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27533448%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

13

Bartosz Chmielowski

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27533448%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

author name string

Alain P Algazi

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27533448%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Katy K Tsai

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27533448%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Alexander N Shoushtari

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27533448%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Rodrigo R Munhoz

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27533448%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Zeynep Eroglu

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27533448%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Patrick A Ott

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27533448%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Douglas B Johnson

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27533448%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Jimmy Hwang

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27533448%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Jeffrey A Sosman

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27533448%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Richard D Carvajal

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27533448%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Michael A Postow

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27533448%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Ryan J Sullivan

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27533448%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

language of work or name

English

0 references

publication date

17 August 2016

1 reference

http://europepmc.org/abstract/PMC/5767160

22 February 2018

number of pages

10

1 reference

based on heuristic

inferred from page(s)

published in

Cancer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27533448%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

volume

122

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27533448%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

issue

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27533448%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

page(s)

3344-3353

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27533448%20AND%20SRC:MED&resulttype=core&format=json

The use of pembrolizumab for the treatment of metastatic uveal melanoma

12 June 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5767160

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5767160

Immunity, tolerance and autoimmunity in the liver: A comprehensive review.

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5767160

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5767160

Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5767160

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5767160

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5767160

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5767160

Pembrolizumab for the treatment of non-small-cell lung cancer

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5767160

Pembrolizumab versus Ipilimumab in Advanced Melanoma

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5767160

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5767160

Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5767160

PD-1 blockade induces responses by inhibiting adaptive immune resistance

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5767160

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5767160

Genetic basis for clinical response to CTLA-4 blockade in melanoma

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5767160

Nivolumab in previously untreated melanoma without BRAF mutation

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5767160

Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5767160

Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5767160

SF3B1 mutations are associated with alternative splicing in uveal melanoma

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5767160

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5767160

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5767160

Mutations in GNA11 in uveal melanoma

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5767160

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5767160

Effectiveness of treatments for metastatic uveal melanoma.

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5767160

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5767160

Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5767160

The association between host susceptibility factors and uveal melanoma: a meta-analysis

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5767160

Epidemiology of tumors affecting the visual system.

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5767160

BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma.

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5767160

Variates of survival in metastatic uveal melanoma.

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5767160

Nonparametric Estimation from Incomplete Observations

15 August 2018

1 reference

Crossref

https://api.crossref.org/works/10.1002%2FCNCR.30258

Prognosis and treatment of disseminated uveal melanoma

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1002%2FCNCR.30258

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/CNCR.30258

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27533448%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27533448%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

PubMed publication ID

27533448

1 reference